Thomas Gajewski - Jounce Therapeutics Insider

JNCE -- USA Stock  

USD 7.83  0.09  1.16%

Dr. Thomas F. Gajewski, M.D. Ph.D. is a scientific cofounder of Jounce Therapeutics and currently serves as professor, departments of pathology and medicine, section of hematologyoncology at the University of Chicago. There, he is leader of the immunology and cancer program of the Cancer Center, and also directs the Melanoma Oncology Clinic. Dr. Gajewski is the immediate past president of the Society for Immunotherapy of Cancer and serves as an editor of Cancer Research and JITC. His laboratory studies the molecular and cellular regulation of T lymphocyte activation and differentiation, and in turn applies this information to preclinical and clinical efforts to promote antitumor immunity in vivo. Dr. Gajewski is committed to investigating and developing new treatments for patients with melanoma, with a special interest in the development of immunotherapies against the disease
Gajewski also leads development of immunebased therapies for other cancers, using new laboratory data on how the immune system is regulated to develop novel clinical trials. He has served on the program committees for the American Society for Clinical Oncology and the American Association for Cancer Research .

Management Efficiency

The company has return on total asset (ROA) of (6.42) % which means that it has lost $6.42 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (20.72) % meaning that it created substantial loss on money invested by shareholders.

Entity Summary

Jounce Therapeutics, Inc., a clinical stage immunotherapy company, develops therapies for the treatment of cancer. The company was incorporated in 2012 and is headquartered in Cambridge, Massachusetts. Jounce Therapeutics operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 112 people.Jounce Therapeutics (JNCE) is traded on BATS Exchange in USA. It is located in MASSACHUSETTS U.S.A and employs 112 people. Jounce Therapeutics is listed under Pharmaceutical Products category by Fama And French industry classification.

Jounce Therapeutics Leadership Team

Barbara Duncan, Director, MBA
Luis Diaz, Director
Drew Pardoll, Founder, Ph.D
Deborah Law, Executive, Ph.D
Richard Murray, CEO, Ph.D
Kimberlee Drapkin, CFO
Robert Kamen, Director, Ph.D
Hugh Cole, Executive, MBA
Thomas Gajewski, Founder
Elizabeth Trehu, Executive
Robert Tepper, Director, Ph.D
Perry Karsen, Chairman
Padmanee Sharma, Founder, Ph.D
Cary Pfeffer, Director, MBA
Duncan Higgons, Director
James Allison, Founder, Ph.D

Stock Performance Indicators

Current Sentiment - JNCE

Jounce Therapeutics Investor Sentiment
Macroaxis portfolio users are indifferent in their judgment towards investing in Jounce Therapeutics. What is your judgment towards investing in Jounce Therapeutics? Are you bullish or bearish?
50% Bullish
50% Bearish

Build Optimal Portfolios

Align your risk with return expectations
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please also check Risk vs Return Analysis. Please also try CEO Directory module to screen ceos from public companies around the world.